Blog

• Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in proteinuria and a safety profile comparable to placebo, with results presented at ASN Kidney Week 2025.

• Atacicept has also received FDA Breakthrough Therapy Designation, underlining its potential as an innovative treatment for autoimmune kidney diseases.

• We’ll explore what the positive ORIGIN Phase 3 data and Breakthrough Therapy Designation mean for Vera Therapeutics’ investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

For shareholders, the core belief revolves around Vera Therapeutics’ ability to successfully bring atacicept to market as an innovative therapy for IgA nephropathy, potentially transforming its clinical and financial trajectory. The recent announcement that the ORIGIN Phase 3 trial met its primary endpoint and achieved a robust reduction in proteinuria, coupled with Breakthrough Therapy Designation, serves as a significant validation of the company’s clinical direction. Previously, the main short-term catalyst centered on regulatory data disclosures and regulatory progress for atacicept. With the latest data now in the spotlight at ASN Kidney Week 2025, the path toward regulatory submission and possible approval is clearer, elevating expectations around these near-term milestones. However, the company’s lack of revenue and ongoing quarterly losses remain major risks, as does future dilution from recent and potential equity offerings. Market interest may increase given the new efficacy data, but execution risk and financing needs persist for Vera despite the promising clinical results.

Otherwise, investors should not overlook the risk of continued operating losses and share dilution. Despite retreating, Vera Therapeutics’ shares might still be trading above their fair value and there could be some more downside. Discover how much.

Across the Simply Wall St Community, fair value estimates for Vera Therapeutics vary widely, spanning from US$72.29 to a very large US$722.93 based on five distinct analyses. While opinions differ on valuation, the company’s breakthrough trial results could shift these perspectives further given the heightened focus on near-term regulatory approval and continued funding requirements. Explore these broader viewpoints to better understand how varying investor expectations shape Vera’s share performance.

Explore 5 other fair value estimates on Vera Therapeutics – why the stock might be a potential multi-bagger!

Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VERA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

eToro Group (NasdaqGS:ETOR) shares have moved up 3% over the past day, catching the attention of investors tracking recent momentum. Over the past month, however, the stock is still down 7%, underlining ongoing volatility in the sector.

See our latest analysis for eToro Group.

While eToro Group’s 1-day share price return of 3.2% has sparked renewed interest, it follows a much steeper loss of nearly 40% over the past quarter. This highlights that recent momentum remains fragile compared to the year’s persistent downward trend.

If you’re tracking fresh movers or seeking overlooked opportunities, now’s a great time to broaden your investing horizons and discover fast growing stocks with high insider ownership

With a steep drop from its recent highs and signs of potential value compared to analyst price targets, is eToro Group undervalued at these levels, or has the market already factored in any future rebound?

eToro Group is trading at a price-to-earnings (P/E) ratio of 17.5x, which is well above the peer average of 6.5x. At the last close price of $39.27, the market is asking investors to pay a significant premium relative to direct competitors.

The price-to-earnings ratio is one of the most commonly used measures to assess if a company’s stock is expensive or cheap versus its earnings. For a diversified financials firm like eToro, this ratio reflects how much growth, stability, and earnings quality investors expect from future performance.

At 17.5x, the P/E is notably higher than the sector’s typical 6.5x. This large gap signals that investors are either confident in eToro’s sustained growth trajectory or potentially overestimating its near-term prospects. Without a supporting fair ratio, this valuation could moderate as market expectations adjust.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 17.5x (OVERVALUED)

However, persistent annual revenue declines and a significant premium to price targets remain near-term risks that could challenge any quick turnaround for eToro shares.

Find out about the key risks to this eToro Group narrative.

While the price-to-earnings ratio shows eToro Group trading at a premium, our DCF model gives a different perspective. According to this approach, eToro’s shares are currently trading about 13% below our estimated fair value. Does the market see risks others are overlooking? Or could there be unrealized potential here?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out eToro Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you have a different perspective or would rather dig into the numbers yourself, you can shape your own narrative in just a few minutes. So why not Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding eToro Group.

Set yourself up for better returns by finding companies with unique advantages. Don’t miss your chance to uncover fresh opportunities beyond just eToro Group.

• Secure your spot in the AI transformation and tap into potential growth by checking out these 27 AI penny stocks, which are taking center stage in innovative industries.

• Earn attractive yields with stability by reviewing these 17 dividend stocks with yields > 3% that offer payouts above 3% for your portfolio.

• Position yourself early in technology’s next revolution by targeting these 27 quantum computing stocks and learn how these companies are shaping the future of quantum computing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ETOR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com